Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 5, 2008, Pages 821-830

  Munkelt, Doreen ^a   Koehl, Ulrike ^a,b   Kloess, Stephan ^a   Zimmermann, Stefanie Yvonne ^a   Kalaäoui, Rabiá El ^a   Wehner, Sibylle ^a   Schwabe, Dirk ^a   Lehrnbecher, Thomas ^a   Schubert, Ralf ^a   Kreuter, Joerg ^b   Klingebiel, Thomas ^a   Esser, Ruth ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Busulfan; Leukemia; Treosulfan

Indexed keywords

BUSULFAN; CASPASE 3; FLUDARABINE; FLUDARABINE PHOSPHATE; TREOSULFAN;

APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOTOXICITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; LOW DRUG DOSE; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BUSULFAN; CASPASE 3; CELL LINE, TUMOR; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; STEM CELLS; T-LYMPHOCYTES; TETRAZOLIUM SALTS; THIAZOLES; VIDARABINE;

EID: 49749112428     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0669-3     Document Type: Article

References (35)

1. D Blaise D Maraninchi E Archimbaud J Reiffers A Devergie JP Jouet N Milpied M Attal M Michallet N Ifrah 1992 Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytotxan-total body irradiation as preparative regimen Blood 79 2578 2582
2. O Beck C Seidl T Lehrnbecher H Kreyenberg D Schwabe T Klingebiel E Seifried P Bader U Koehl 2006 Quantification of chimerism within peripheral blood, bone marrow and purified leukocyte subsets: comparison of singleplex and multiplex PCR amplification of short tandem repeat (STR) loci Eur J Haematol 76 237 244
3. DW Beelen R Trenschel J Casper M Freund RA Hilger ME Scheulen N Basara AA Fauser B Hertenstein HA Mylius J Baumgart U Pichlmeier JR Hahn E Holler 2005 Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications Bone Marrow Transplant 35 233 241
4. MC Bene G Castoldi W Knapp WD Ludwig E Matutes A Orfao MB vańt Veer 1995 Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL) Leukemia 9 1783 1786
5. AG Bosanquet AR Burlton 1994 Airborne cytotoxicity in the DiSC assay caused by solutions of treosulfan but not busulphan Cytotechnology 16 131 136
6. J Casper W Knauf T Kiefer D Wolff B Steiner U Hammer R Wegener HD Kleine S Wilhelm A Knopp G Hartung G Dölken M Freund 2004 Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic haematopoietic stem cell transplantation Blood 103 725 731
7. TC Chou P Talalay 1988 Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55
8. M Den Boer DO Harms R Pieters KM Kazemier U Gobel D Körholz U Graubner RJ Haas N Jorch HJ Spaar GJ Kaspers WA Kamps A Van der den Does-Van Berg ER Van Wering AJ Veerman GE Janka-Schaub 2003 Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia J Clin Oncol 21 3262 3268
9. F Di Nicolantonio LA Knight S Di Palma S Sharma PA Whitehouse SJ Mercer PA Charlton D Norris IA Cree 2004 Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors Anticancer Drugs 15 849 860
10. K Drabko J Zawitkowska-Klaczynska B Wojcik M Choma A Zaucha-Prazmo J Kowalczyk E Gorczynska J Toporski K Kalwak D Turkiewicz A Chybicka 2005 Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma Pediatr Transplant 9 618 621
11. S Feyerabend G Feil J Krug A Kassen A Stenzl 2007 Cytotoxic effects of treosulfan on prostate cancer cell lines Anticancer Res 27 2403 2408
12. I Fichtner M Becker J Baumgart 2003 Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL) Eur J Cancer 39 801 807
13. MI Gutiérrez AK Siraj MM Ibrahim A Hussain K Bhatia 2005 Childood and adult ALL: differences in epigenetic lesions associated with cell cycle genes Am J Hematol 80 158 160
14. RA Hilger A Harstrick W Eberhardt C Oberhoff M Skorzec J Baumgart S Seeber ME Scheulen 1998 Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumours Cancer Chemother Pharmacol 42 99 104
15. U Koehl R Esser S Zimmermann T Tonn R Kotchetkov T Bartling J Sörensen HP Grüttner P Bader E Seifried H Martin P Lang J Passweg T Klingebiel D Schwabe 2005 Ex vivo expansion of highly purified NK-cells for immunotherapy after haploidentical stem cell transplantation in children Klin Padiatr 217 345 350
16. P Kopf- Maier 1998 The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro In vivo 12 275 288
17. N Kröger A Shimoni T Zabelina H Schieder J Panse F Ayuk C Wolschke H Renges J Dahlke D Atanackovic A Nagler A Zander 2006 Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS) Bone Marrow Transplant 37 339 344
18. C Lanvers-Kaminsky A Bremer U Dirksen H Jurgens J Boos 2006 Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines Anticancer Drugs 17 657 662
19. MR Litzow WS Prez JP Klein BJ Bollwell B Camitta EA Copelan RP Gale SA Giralt A Keating HM Lazarus DI Marjus PL McCarthy CB Miller G Milone HG Prentice JA Russel KR Schultz ME Trigg DJ Weisdorf MM Horowitz 2002 Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning regimen for acute myelogenous leukaemia in first remission Br J Haematol 119 1115 1124
20. G Meinhardt F Dayyani B Jahrsdörfer J Baumgart B Emmerich R Schmidmaier 2003 Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients Br J Haematol 122 892 899
21. T Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 55 63
22. RE Ploemacher KW Johnson EJC Rombouts E Kenol GR Westerhof J Baumgart ME White-Scharf JD Down 2004 Addition of Treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model Biol Blood Marrow Transplant 10 236 245
23. BJ Sanderson KJ Johnson WD Henner 1991 Dose-dependent cytotoxic and mutagenic effects of antineoplastic alkylating agents on human lymphoblastoid cells Environ Mol Mutagen 17 238 243
24. U Sanyal R Nanda S Samanta A Pain S Dutta AS Verma BJ Rider KC Agrawal 2000 Evaluation of dimethylaminosulfonates of alkane diols as a novel group of anticancer agents Cancer Lett 155 89 97
25. M Sauer C Zeidler B Meissner K Rehe A Hanke K Welte P Lohse K-W Sykora 2007 Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome Bone Marrow Transplant 39 143 147
26. ME Scheulen RA Hilger C Oberhoff J Casper M Freund KM Josten M Bornhauser G Ehninger WE Berdel J Baumgart A Harstrick P Bojko HH Wolf AE Schindler S Seeber 2000 Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies Clin Cancer Res 6 4209 4216
27. R Schmidmaier M Oellerich J Baumgart B Emmerich G Meinhardt 2004 Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1 Exp Hematol 32 76 96
28. R Schmidmaier P Baumann B Emmerich G Meinhardt 2006 Evaluation of chemosensitivity of human bone marrow stromal cells-differences between common chemotherapeutic drugs Anticaner Res 26 347 350
29. F Sjoo Z Hassan M Abedi-Valugerdi L Griskevicius C Nilsson M Remberger J Aschan H Concha U Gaughan M Hassan 2006 Myeloablative and immunosuppressive properties of treosulfan in mice Exp Hematol 34 115 121
30. J Styczynski J Toporski M Wysocki R Debski A Chybicka D Boruczkowski J Wachowiak B Wojcik J Kowalczyk L Gil W Balwierz M Matysiak M Krawczuk-Rybak A Balcerska D Sonta-Jakimczyk 2007 Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia Anticancer Res 27 1547 1552
31. G Vassal S Koscielny D Challine D Valteau-Couanet I Boland A Deroussent J Lemerle A Gouyette O Hartmann 1996 Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation Cancer Chemother Pharmacol 37 247 253
32. JM Vergnon S Boucheron J Riffat C Guy P Blanc A Emonot 1988 Interstitial pneumopathies caused by busulfan. Histologic, developmental and bronchoalveolar lavage analysis of 3 cases Rev Med Interne 9 377 383
33. Werner S, Mendoza A, Hilger RA, Erlacher M, Reichardt W, Lissat A, Konanz C, Uhl M, Niemeyer CM, Khanna C, Kontny U (2007) Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Cancer Chemother Pharmacol. (Epub ahead of print)
34. GR Westerhof RE Ploemacher A Boudewijn I Blokland JH Dillingh AT McGown JA Hadfield MJ Dawson JD Down 2000 Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients Cancer Res 60 5470 5478
35. SY Zimmermann R Esser E Rohrbach T Klingebiel U Koehl 2005 A novel four-colour flowcytometric assay to determine natural killer cell or T cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells J Immunol Methods 296 63 76